Beyond the Last Resort: A New Dawn for Advanced Prostate Cancer

For individuals diagnosed with advanced prostate cancer that has ceased responding to conventional hormonal interventions, therapeutic avenues become significantly restricted, underscoring the critical nature of timely treatment. As the disease advances, the window for implementing less invasive yet efficacious therapeutic strategies progressively narrows.

A collaborative clinical investigation, spearheaded by medical professionals from the Medical University of South Carolina (MUSC) and Emory University, evaluated the potential of an experimental pharmaceutical agent to prolong the efficacy of established treatments. This comprehensive study, detailed in the publication Cancer Medicine, explored an innovative methodology aimed at mitigating treatment resistance in advanced prostate cancer.

This patient cohort presents considerable therapeutic challenges. These individuals have cancer that has already developed resistance to standard protocols, thus highlighting an undeniable demand for novel interventions.”

Besim Ogretmen, PhD, Co-Author of the Study and Associate Director of Basic Science at the Hollings Cancer Center, Medical University of South Carolina

Efforts to Enhance the Durability of Current Therapies

The research specifically targeted men afflicted with metastatic castration-resistant prostate cancer, a particularly aggressive manifestation of the disease characterized by its spread to other body parts and its unresponsiveness to hormone-suppressing treatments.

These standard therapies, notably abiraterone and enzalutamide, initially demonstrate considerable effectiveness. However, the majority of patients eventually develop a resistance to these drugs, leaving them with a limited array of subsequent options, frequently necessitating a transition to chemotherapy, which can be accompanied by substantial adverse effects.

“We are perpetually seeking new therapeutic targets,” stated Omer Kucuk, M.D., an oncologist and the Correll Chair in Genitourinary Cancer at Winship Cancer Center of Emory University, which played a pivotal role in patient recruitment and clinical execution. “Following the failure of androgen receptor therapies, specific, personalized treatment choices become scarce.”

Rather than supplanting these established treatments, the research team investigated whether the concurrent administration of an additional oral medication could augment their effectiveness, improve patient prognoses, and extend the duration of the therapeutic response.

Progression from MUSC Discovery to Clinical Application

The experimental compound at the core of this investigation — opaganib — originated from research conducted at MUSC.

Opaganib, a pioneering therapeutic agent, was developed based on seminal research led by Charles Smith, Ph.D., and subsequently advanced through extensive laboratory work and early-stage trials at MUSC. This process included an initial-phase clinical trial administered at Hollings, which then paved the way for this present mid-phase clinical trial. This subsequent trial was overseen by Hollings oncologist Michael Lilly, M.D., now a professor emeritus, who was instrumental in guiding the drug from its initial discovery phase into patient care.

“This endeavor is built upon years of preclinical and early clinical investigations,” commented Ogretmen. “Our objective was to leverage our laboratory findings to ascertain if we could enhance patient outcomes.”

Crucially, opaganib operates via a distinct mechanism compared to conventional therapies. It does not target hormones but instead inhibits a cellular pathway involved in sphingolipid metabolism — a cellular process for managing lipids, or fats, that influence cell viability. This metabolic pathway is increasingly attracting the attention of researchers, as dysregulation in fat metabolism is believed to contribute to cancer proliferation and treatment resistance.

“There are few pharmaceuticals currently available that target this particular pathway,” noted Kucuk. “This makes the approach highly promising and significantly different from the treatments we currently employ.”

Preliminary Indications of Therapeutic Efficacy

Within this Phase 2 trial, a total of 66 patients received opaganib in conjunction with either abiraterone or enzalutamide following disease progression.

Approximately 15% of patients administered opaganib alongside abiraterone, and 9% receiving it with enzalutamide, demonstrated disease control at the 16-week mark, which fell short of the study’s primary objective. Nevertheless, a more detailed scrutiny revealed a more complex and encouraging scenario.

A discernible subset of participants exhibited clear biological indicators of a positive response, including reductions in prostate-specific antigen (PSA) levels and periods of disease stabilization. These findings suggest that the therapeutic intervention may be effective in decelerating the progression of the disease and enabling patients to remain on their current treatment regimen for longer durations.

“While this represents a modest proportion, these are tangible benefits for actual patients,” Ogretmen emphasized. “We are referring to individuals who are experiencing positive outcomes from this treatment when other approaches have failed.”

Beyond its efficacy, the drug’s tolerability profile constitutes another significant aspect of this research. The combined therapeutic regimen was generally well-tolerated, with most reported side effects being mild to moderate in severity. Although some patients experienced more severe adverse events, these were largely alleviated through dose reduction or discontinuation of the medication.

Paving the Way for Precision Medicine

According to the research team, these findings signify a substantial advancement by identifying a novel biological pathway for targeting prostate cancer. A critical subsequent step involves pinpointing the patient population most likely to derive benefit from this drug combination.

By analyzing blood samples collected from trial participants, the researchers intend to identify biomarkers — measurable indicators in the blood — that can predict treatment response. This methodology holds the potential to refine the therapeutic strategy for a more select group of patients, a defining characteristic of precision medicine.

“We can investigate how lipid profiles change in patients who respond favorably compared to those who do not,” Ogretmen explained. “This may assist us in stratifying patients and more accurately aligning the treatment with the individual.”

The study, which received partial funding through a program project grant from the National Cancer Institute (NCI) awarded to Ogretmen and his team, also underscores the profound impact of collaborative efforts, bringing together expertise from MUSC and Emory to facilitate the transition of a scientific discovery from the laboratory to clinical application.

“This was an exceptional collaboration between the two institutions,” Kucuk remarked. “It represents a highly innovative approach, and it was gratifying to be involved in bringing it to a clinical setting.”

“This type of advancement is contingent upon robust partnerships among academic researchers, clinicians, and industry collaborators,” Ogretmen added. “This synergy is essential for delivering new therapies to patients who currently lack effective treatment options.”

Looking forward, the researchers express optimism that further refinement of this strategy or the development of next-generation therapeutics targeting the same pathway could broaden the scope of available treatment options. There is a growing sense of hope that these interventions may become integral components of future therapeutic paradigms.